FDA Approves Generic Versions of Lilly's Antidepressant Cymbalta
The FDA has granted approval for the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription antidepressant that is currently Eli Lilly's top-selling drug.
Cymbalta's patent expired Wednesday, opening doors for six generic drugmakers. Teva Pharmaceuticals USA as well as India's Aurobindo Pharma, Dr. Reddy’s Laboratories, Lupin, Sun Pharma Global and Torrent Pharmaceuticals have received FDA approval to market duloxetine in various strengths.
According to AP News, Lilly's Cymbalta posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world.